In addition, tazemetostat, an inhibitor of EZH2, suppressed CCR8 expression in TAX-expressing T cells (Figure 1E), which was consistent with the finding that EZH2 was associated with ATLL cell development and interacted with TAX (24). Here, CCR8 is linked to adult T-cell leukemia/lymphoma.